Study guide
4.2 Neuroblastoma
Certified Pediatric Hematology Oncology Nurse CPHON®
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current Exam Facts 1.2 Eligibility, Application, and Testing Logistics 1.3 Test Content Outline and Study Strategy
2 Care Continuum
2.1 Transition of Care: Primary Care and Levels of Care 2.2 End-of-Life Care 2.3 Health Promotion and Maintenance 2.4 Survivorship
3 Leukemias and Lymphomas
3.1 Acute Lymphoblastic Leukemia 3.2 Acute Myeloid Leukemia and Related Myeloid Disease 3.3 Hodgkin and Non-Hodgkin Lymphomas
4 CNS, Neuroblastoma, and Renal Tumors
4.1 Central Nervous System Tumors 4.2 Neuroblastoma 4.3 Wilms Tumor and Other Renal Tumors
5 Sarcomas and Other Solid Tumors
5.1 Osteosarcoma and Ewing Sarcoma 5.2 Rhabdomyosarcoma and Soft-Tissue Sarcomas 5.3 Retinoblastoma, Hepatoblastoma, and Germ Cell Tumors
6 Hematologic Disorders
6.1 Sickle Cell Disease 6.2 Thalassemia and Other Hemoglobinopathies 6.3 Hemophilia, von Willebrand Disease, and Coagulopathies 6.4 Immune Thrombocytopenia, Aplastic Anemia, and Bone Marrow Failure
7 Pathophysiology, Genetics, and Diagnostics
7.1 Anatomy, Physiology, and Pathophysiology Foundations 7.2 Genetics and Genomics 7.3 Diagnostic Testing, Staging, and Prognosis
8 Clinical Trials and Professional Performance
8.1 Clinical Trials and Informed Consent 8.2 Scope, Standards, and Regulatory Practice 8.3 Ethics and Patient-Family Education
9 Chemotherapy and Biotherapy
9.1 Chemotherapy Principles, Classes, and Pediatric Protocols 9.2 Safe Handling, Administration, and Vesicant Precautions 9.3 Biotherapy
10 Immunotherapy, Cellular Therapy, and Radiation
10.1 Immunotherapy 10.2 Cellular Therapies including CAR-T 10.3 Radiation Therapy, I-131-MIBG, and Proton Beam
11 HSCT, Surgery, Transfusion, and Coagulation Therapy
11.1 Hematopoietic Stem Cell Transplantation 11.2 Surgical Management 11.3 Blood Product Therapy, Leukapheresis, and Coagulation Therapy
12 Neurologic, Respiratory, and Cardiovascular Effects
12.1 Neurological Acute, Chronic, and Late Effects 12.2 Respiratory and Lymphatic Effects 12.3 Cardiovascular Effects
13 Gastrointestinal, Renal, Musculoskeletal, and Integumentary Effects
13.1 Gastrointestinal Effects 13.2 Renal and Genitourinary Effects 13.3 Musculoskeletal and Integumentary Effects
14 Endocrine, Hematologic, Immunologic, and Sensory Effects
14.1 Endocrine and Reproductive Effects 14.2 Hematological and Immunological Effects 14.3 Ophthalmological and Otological Effects
15 Pain, Sleep, Fatigue, and Mental Health
15.1 Pain Assessment and Management 15.2 Sleep Disturbance and Fatigue 15.3 Mental Health Effects
16 Supportive Care
16.1 Medical Devices: Venous Access, Pumps, Shunts, and Tubes 16.2 Blood Product Administration 16.3 Colony-Stimulating Factors 16.4 Interdisciplinary, Palliative, and Complementary Care
17 Infectious and Gastrointestinal Emergencies
17.1 Sepsis 17.2 Typhlitis 17.3 Pancreatitis and Bowel Obstruction
18 Metabolic Emergencies
18.1 Diabetes Insipidus and SIADH 18.2 Tumor Lysis Syndrome 18.3 Cytokine Release Syndrome
19 DIC, Hyperleukocytosis, and Sinusoidal Obstructive Syndrome
19.1 Disseminated Intravascular Coagulation and Hemorrhage 19.2 Hyperleukocytosis 19.3 Sinusoidal Obstructive Syndrome (Veno-Occlusive Disease)
20 Sickle Cell and Hemostasis Emergencies
20.1 Splenic Sequestration 20.2 Vaso-Occlusive Crisis 20.3 Stroke, Thrombosis, and Joint Bleed
21 Cardiopulmonary Emergencies
21.1 Acute Chest Syndrome 21.2 Respiratory Distress and Mediastinal Mass 21.3 Pleural Effusions and Arrhythmias
22 Neurologic and Infusion Emergencies
22.1 Increased Intracranial Pressure 22.2 Seizures and PRES 22.3 Spinal Cord Compression 22.4 Hypersensitivity Reactions and Extravasation
23 Family, Caregivers, and Social Integration
23.1 Effects of Acute and Chronic Illness on Patient and Family 23.2 Patient and Family/Caregiver Support 23.3 Integration into Family, School, Work, Camp, and Social Environment
24 Development, Grief, Culture, and Community Resources
24.1 Principles of Growth and Development 24.2 Grief and Bereavement 24.3 Culture, Sexuality and Gender, Socioeconomics, and Community Resources
4.2 Neuroblastoma
Key Takeaways Explain This Topic AI
Neuroblastoma is the most common extracranial solid tumor of childhood, arising from the adrenal medulla or sympathetic chain, with peak incidence in infancy and the toddler years.
Hallmark presentations include abdominal mass, raccoon-eye orbital metastases, blueberry-muffin skin nodules, opsoclonus-myoclonus, spinal cord compression, and VIP secretory diarrhea.
Staging workup is urine HVA and VMA, cross-sectional imaging, MIBG scan, bilateral bone marrow, and biopsy for MYCN, histology, and ploidy.
INRG risk uses age, stage, MYCN, histology, and ploidy; selected perinatal adrenal tumors with favorable biology may be observed rather than treated intensively.
High-risk therapy is a sequence: induction, surgery, consolidation that may include tandem HSCT or other consolidations, then dinutuximab (anti-GD2) plus cytokines; I-131-MIBG is for refractory avid disease. Anti-GD2 nursing centers on neuropathic pain, capillary leak, and hypotension.
Last updated: August 2026
Neuroblastoma is the most common extracranial solid tumor of childhood . It arises from neural-crest cells of the adrenal medulla or the sympathetic chain —paraspinal abdomen, thorax, neck, or pelvis. Peak incidence is infancy and the toddler years , with many diagnoses before age 2. CPHON items test the strange presentations, the catecholamine and metaiodobenzylguanidine (MIBG) workup, International Neuroblastoma Risk Group (INRG) assignment, and the high-risk modality sequence. Do not treat one cooperative-group protocol acronym as if it were the only 2026 law; teach the order of modalities.
How the tumor announces itself
A toddler’s abdominal mass may be found in the bath. Thoracic tumors cause cough, respiratory distress, or Horner syndrome (ptosis, miosis, anhidrosis) when the cervical-thoracic chain is involved. Paraspinal dumbbell tumors grow through neural foramina and cause spinal cord compression : a toddler who stops walking, develops a sensory level, or cannot empty the bladder needs emergency MRI and cord-directed therapy, not a wait-until-Monday clinic slot.
Metastatic signs are exam classics. Raccoon-eye periorbital ecchymoses reflect orbital bony metastases and are not just a fall when an abdominal mass is present. Blueberry-muffin lesions are dermal metastases, more often in infants. Opsoclonus-myoclonus syndrome (OMS) —chaotic dancing eyes, myoclonic jerks, and ataxia—is a paraneoplastic syndrome. The primary tumor may be small, but the neurologic injury can be lasting, so treat OMS as both an oncologic and a neuroinflammatory emergency. Vasoactive intestinal peptide (VIP) secretion causes watery secretory diarrhea and hypokalemia. Catecholamine effects can include hypertension and flushing, but VIP diarrhea is the board-style gastrointestinal clue.
A 15-month-old with raccoon eyes, a hard abdominal flank mass, and darting eyes is metastatic neuroblastoma until the workup says otherwise. Do not close the chart as isolated trauma when the belly is full, and do not call it Wilms tumor: Wilms does not produce raccoon-eye marrow-and-bone metastases as its signature.
Workup that assigns risk
Send urine homovanillic acid (HVA) and vanillylmandelic acid (VMA) —catecholamine metabolites. Image the primary with MRI or computed tomography, then stage with MIBG scan (neuroblastoma cells take up this norepinephrine analog), bilateral bone marrow aspirate and biopsy, and a tissue biopsy for histology, MYCN status, ploidy, and other biologic features. MIBG-negative disease needs an alternative functional study per team practice, often fluorodeoxyglucose positron-emission tomography. Do not skip marrow: cortical bone and marrow metastases define high-stage disease.
Finding Points toward neuroblastoma Nursing action
Adrenal or paraspinal mass in an infant or toddler Primary along the sympathetic axis Protect the abdomen; prepare for biopsy and staging
- Raccoon-eye ecchymoses Orbital metastases Do not assume trauma in isolation
- Blueberry-muffin skin nodules Dermal metastases, often infants Photograph, biopsy plan, family teaching
- Opsoclonus-myoclonus Paraneoplastic OMS Neurology plus oncology; rehabilitation early
Flaccid legs, sphincter change Cord compression from a dumbbell tumor Emergency MRI; steroids, chemotherapy, or surgery per team
- Watery diarrhea, hypokalemia VIP secretion Fluid and potassium; tumor-directed therapy
- Elevated urine HVA/VMA Catecholamine-producing tumor Spot or timed urine per laboratory protocol
- MIBG-avid sites Neuroblastoma-specific staging Isolation teaching later if iodine-131 therapy is used
- INRG risk: what actually changes treatment
INRG staging uses image-defined risk factors to label L1 (localized, no image-defined risk factors), L2 (locoregional with risk factors), M (distant metastatic), and MS (metastatic disease in children younger than 18 months limited to skin, liver, and/or limited marrow—the group formerly called 4S). Risk assignment then layers age , stage , MYCN amplification, histology (International Neuroblastoma Pathology Classification), and ploidy . MYCN-amplified tumors are treated as high-risk even when the scan looks localized. Infants with MS disease and favorable biology can do remarkably well; the same metastatic pattern in a 4-year-old with MYCN amplification is a different disease.
Localized versus metastatic is not the whole story. A perinatal infant with a small adrenal mass and favorable biology may be a candidate for observation . A preschooler with marrow and bone metastases is on a high-risk pathway. Teach families that stage without age and MYCN is an incomplete sentence.
Treatment as a sequence of modalities
Observation is appropriate for selected perinatal adrenal neuroblastomas with favorable features; serial ultrasound and urine catecholamines replace immediate resection for that carefully chosen group.
Surgery is local control for L1 and selected L2 tumors and is cytoreduction after induction in high-risk disease. Cord compression may need urgent chemotherapy, laminotomy or laminectomy, or both.
Chemotherapy is the backbone of intermediate- and high-risk treatment. Induction typically uses combinations that may include cyclophosphamide, doxorubicin, vincristine, cisplatin, and etoposide—generic names, protocol-dependent.
High-risk disease then moves to consolidation . Contemporary Children’s Oncology Group (COG)–style high-risk approaches have used tandem autologous hematopoietic stem cell transplantation (HSCT) or other intensified consolidations. After consolidation, local radiation to residual primary and selected metastatic sites is common.
Dinutuximab , a monoclonal anti-GD2 antibody, plus cytokines (granulocyte-macrophage colony-stimulating factor is the cytokine most consistently paired in current practice; interleukin-2 was used historically and is more toxic) is immunotherapy after high-risk consolidation, often with oral isotretinoin as a differentiating agent. Iodine-131 metaiodobenzylguanidine (I-131-MIBG) is a targeted radiopharmaceutical for MIBG-avid refractory or relapsed disease, not first-line therapy for a tiny perinatal L1 adrenal mass.
Anti-GD2 nursing is a CPHON skill
GD2 is expressed on neuroblastoma and on peripheral nerve. Dinutuximab therefore causes neuropathic pain during the infusion. Plan a standing opioid infusion and adjuncts per protocol; do not wait for the child to prove pain, and do not withhold analgesia because pain means it is working. Capillary leak produces edema, rapid weight gain, hypoxia, and a rising oxygen requirement. Hypotension is expected enough that blood pressure is a vital sign, not an afterthought; have fluid-bolus orders and hold parameters ready. Fever, urticaria, and true hypersensitivity also occur. Premedication, slow titration, and intensive-care-capable monitoring during early doses are standard in many centers.
I-131-MIBG adds radiation isolation, thyroid blockade so free iodide does not irradiate the thyroid, caregiver film-badge teaching, and myelosuppression that can require stem-cell backup.
A 3-week-old with a 2-cm adrenal mass and a 3-year-old with MYCN-amplified marrow disease should not leave the teaching session sounding like the same protocol. Observation versus induction, consolidation, then anti-GD2—plus pain and leak precautions for dinutuximab—is the CPHON distinction.